ONCY News and Press, Oncolytics Biotech Inc. From 10/19/20

Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board World-renowned scientist specializing in oncolytic viruses and immuno-oncology PR Newswire SAN DIEGO and CALGARY, AB, Oct. 19, 2020 SAN DIEGO and CALGARY, AB , Oct. ...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 8, 2020 – USA News Group – A newly released report titled “Immunotherapy Drugs Market by Type, Therapy Area, End User – Global Forecast to 2025” fo...

Oncolytics Biotech® to Participate in BIO Investor Forum Digital Canada NewsWire SAN DIEGO and CALGARY, AB, Oct. 7, 2020 SAN DIEGO and CALGARY, AB , Oct. 7, 2020 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announc...

SAN DIEGO and CALGARY, Alberta , Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September: LD Micro 500 Virtual Investor Co...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

CytoDyn advances enrolment in Phase 3 COVID-19 trial CytoDyn Inc. ( CYDY ) announced that it has completed the enrollment for Phase 3 trial for COVID-19 patients with severe-to-critical symptoms. The trial is now eligible for an interim analysis following the 28-day phase. Leronlimab (PR...

August 26, 2020 Palm Beach, FL –August 26, 2020 – Although various market revenue projections may differ in the total dollar figures, the reports in the triple negative breast cancer (TNBC) treatment market all predict a sustainable growth oner the next several years...

Oncolytics Biotech (NASDAQ: ONCY ) has dosed first patient in Phase 2 IRENE study of Company's pelareorep in combination with Incyte's (NASDAQ: INCY ) anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in unresectable locally advanced or metastatic triple-negative breast ...

- Expansion of Oncolytics' lead breast cancer program into a new disease subtype - Seek synergies between pelareorep and retifanlimab checkpoint inhibitor SAN DIEGO, Calif. and CALGARY, Alberta , Aug. 26, 2020 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ...

In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently placed a giant $6 billion bet on an antibody-drug conjugate (ADC) called DS-1062 from Japanese developers Daiichi Sankyo. The move signalled AZ's confidence that this solid tumor drug coul...